-
FDA Transparency Task Force Will Hold Its Second Public Meeting On November 3, 2009
Emerging Safety Issues Concerning FDA-Regulated Products Is One Issue For Discussion Listed in October 2009 Federal Register Notice (Posted by Tom Lamb at DrugInjuryWatch.com) In the Federal Register for October 5, 2009 the FDA…
-
October 2009: Yasmin And Yaz Multidistrict Litigation (MDL) Transfer Order For Injury And Death Cases Filed In Federal Court
MDL No. 2100 — IN RE: Yasmin and Yaz (Drospirenone) Marketing and Sales Practices and Products Liability Litigation — Assigned To Southern District of Illinois (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: Our Focus…
-
FDA Wants Merck To Change Januvia Label With Increased Warning About Pancreatitis Risk
Is Januvia Similar To Byetta In Terms Of The So-Called Class Effect And Drug Injury Lawsuits Being Filed? (Posted by Tom Lamb at DrugInjuryWatch.com) On September 25, 2009 the FDA posted on its web…
-
Asthma Drug Xolair Is Being Investigated By FDA For Possible Cardiac Problems
Serious Side Effects Include Heart Attacks, Abnormal Heart Rhythms, Heart Failure, And Various Conditions Caused By Blood Clots (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "Xolair Is Associated With Higher Than Expected Reporting…
-
Drug-Company Sponsored Ghostwriters Are Getting Busted By Some Medical Journals
Drug Industry Document Archive (DIDA) Adds Newly Released Wyeth Ghostwriting Documents In September 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) A September 18, 2009 article, "Medical Editors Push for Crackdown on Ghostwriting", published by…
